Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

被引：0
|
作者：
Marc De Hert
Johan Detraux
Ruud van Winkel
Weiping Yu
Christoph U. Correll
机构：
[1] University Psychiatric Center,Department of Psychiatry and Psychology
[2] Catholic University Leuven,undefined
[3] South Limburg Mental Health Research and Teaching Network,undefined
[4] Maastricht University Medical Center,undefined
[5]  The Zucker Hillside Hospital,undefined
[6] Psychiatry Research,undefined
来源：
Nature Reviews Endocrinology | 2012年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The contribution of antipsychotic medications to an increased risk of type 2 diabetes mellitus and cardiovascular disease is controversial. Despite existing guidelines and recommendations, many antipsychotic-drug-treated patients are not routinely assessed for metabolic and cardiac risk factors. This Review outlines the metabolic and cardiovascular risks of various antipsychotic medications in adults and children, defines the disparities in health care and makes recommendations for screening and monitoring of patients taking these agents.
引用
收藏
页码：114 / 126
页数：12
相关论文
共 50 条
  • [31] Effects of antipsychotic drugs on cardiovascular variability in participants with bipolar disorder
    Linder, Jonathan R.
    Sodhi, Simrit K.
    Haynes, William G.
    Fiedorowicz, Jess G.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2014, 29 (02) : 145 - 151
  • [32] Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs
    D E Adkins
    K Åberg
    J L McClay
    J Bukszár
    Z Zhao
    P Jia
    T S Stroup
    D Perkins
    J P McEvoy
    J A Lieberman
    P F Sullivan
    E J C G van den Oord
    Molecular Psychiatry, 2011, 16 : 321 - 332
  • [33] Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs
    Adkins, D. E.
    Aberg, K.
    McClay, J. L.
    Bukszar, J.
    Zhao, Z.
    Jia, P.
    Stroup, T. S.
    Perkins, D.
    McEvoy, J. P.
    Lieberman, J. A.
    Sullivan, P. F.
    van den Oord, E. J. C. G.
    MOLECULAR PSYCHIATRY, 2011, 16 (03) : 321 - 332
  • [34] ADVERSE REACTIONS OF ANTIPSYCHOTIC-DRUGS
    INOUE, F
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1979, 13 (04): : 198 - 208
  • [35] Adverse effects of antipsychotic drugs: survey of doctors’ versus patients’ perspective
    Michela Nosè
    Maria Angela Mazzi
    Eleonora Esposito
    Marco Bianchini
    Paola Petrosemolo
    Giovanni Ostuzzi
    Michele Tansella
    Corrado Barbui
    Social Psychiatry and Psychiatric Epidemiology, 2012, 47 : 157 - 164
  • [36] Adverse effects of antipsychotic drugs: survey of doctors' versus patients' perspective
    Nose, Michela
    Mazzi, Maria Angela
    Esposito, Eleonora
    Bianchini, Marco
    Petrosemolo, Paola
    Ostuzzi, Giovanni
    Tansella, Michele
    Barbui, Corrado
    SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 2012, 47 (01) : 157 - 164
  • [37] Neuroreceptor targets for antipsychotic drugs: implications for treatment efficacy and adverse effects
    Masand, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S605 - S605
  • [38] Implementing guideline recommendations for managing metabolic adverse effects of antipsychotic medications
    Stirewalt, EM
    Miller, DD
    Singer, B
    Arena, J
    Buckley, PF
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 570 - 571
  • [39] Prolactin-related and metabolic adverse effects of atypical antipsychotic agents
    Henderson, David C.
    Doraiswamy, P. Murali
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 : 32 - 44
  • [40] Metabolic effects associated with antipsychotic therapy in a naturalistic setting
    Schreinzer, D
    Letmaier, M
    Barnas, C
    Kasper, S
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S335 - S336
12345